Janssen COVID-19 Vaccine (Johnson & Johnson)
Protocol for Administering Vaccine to Persons 18 Years of Age and Older

Note: For more information/guidance, please contact the immunization program at your state or local health department or the appropriate state body (e.g., state board of medical/nursing/pharmacy practice).

» Purpose
- To reduce morbidity and mortality from coronavirus disease 2019 (COVID-19) by vaccinating persons who meet the criteria established by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP).

» Policy
- Enable eligible nurses and other healthcare professionals (e.g., pharmacists) to assess and vaccinate persons who meet the criteria in the “Procedure” section below without the need for clinician examination or direct order from the attending provider at the time of the interaction.

» Procedure
- Assess persons 18 years of age and older for vaccination with Janssen COVID-19 Vaccine based on the following criteria:
  - Has not completed a COVID-19 vaccination series, regardless of brand.
    - The Janssen COVID-19 Vaccine requires 1 dose. No additional doses are needed.
    - If the recipient has received 1 previous dose of an mRNA vaccine, the same brand should be administered for the second dose.
    - In situations where the first dose of an mRNA COVID-19 vaccine was received but the patient is unable to complete the series with either the same or different mRNA COVID-19 vaccine (e.g., due to contraindication) consideration may be given to vaccination with Janssen COVID-19 Vaccine at a minimum interval of 28 days from the mRNA COVID-19 vaccine dose. However, vaccination should be done in an appropriate setting under the supervision of a healthcare provider experienced in the management of severe allergic reactions. Consider referral to an allergist-immunologist. See footnote for further information on administering Janssen COVID-19 Vaccine to persons with a contraindication to mRNA COVID-19 vaccines.‡
- Janssen COVID-19 Vaccine should not be administered at the same time as other vaccines. Administer the vaccine alone, with a minimum interval of 14 days before or after administration of any other vaccine.*
- Defer vaccination with Janssen COVID-19 Vaccine for at least 90 days for persons who received passive antibody therapy (monoclonal antibodies or convalescent plasma) as part of COVID-19 treatment.

» Screen for contraindications and precautions.
- Contraindications
  - Severe allergic reaction (e.g., anaphylaxis) to a component of Janssen COVID-19 Vaccine
  - Immediate allergic reaction† of any severity or known (diagnosed) allergy to a component of the vaccine (see Table 1 in this document for a list of ingredients in COVID-19 vaccines)
- Precautions
  - History of an immediate allergic reaction† to any other vaccine or injectable therapy (i.e., intramuscular, intravenous, or subcutaneous vaccines or therapies)
    - This includes persons with a reaction to a vaccine or injectable therapy that contains multiple components, one of which is polysorbate or another vaccine component, but for whom it is unknown which component elicited the immediate allergic reaction.
    - People with a contraindication to an mRNA COVID-19 vaccine have a precaution to the Janssen COVID-19 Vaccine (see footnote).±
    - People with a contraindication to Janssen COVID-19 Vaccine (including due to a known polysorbate allergy) have a precaution to mRNA COVID-19 vaccination.

*However, Janssen COVID-19 and other vaccines may be administered within a shorter period in situations where the benefits of vaccination are deemed to outweigh the potential unknown risks of

‡Consultation with an allergist-immunologist should be considered to help determine if the patient can safely receive vaccination. Healthcare providers and health departments may also request a consultation from the Clinical Immunization Safety Assessment COVIDvax Project. Vaccination of these individuals should only be done in an appropriate setting under the supervision of a healthcare provider experienced in the management of severe allergic reactions.
- People with a contraindication to mRNA COVID-19 vaccines (including due to a known PEG allergy) have a precaution to Janssen COVID-19 vaccination. People who have previously received an mRNA COVID-19 vaccine dose should wait at least 28 days to receive Janssen COVID-19 Vaccine.
- People with a contraindication to Janssen COVID-19 Vaccine (including due to a known polysorbate allergy) have a precaution to mRNA COVID-19 vaccination.

*People with a contraindication to mRNA COVID-19 vaccines (including due to a known PEG allergy) have a precaution to Janssen COVID-19 vaccination. People who have previously received an mRNA COVID-19 vaccine dose should wait at least 28 days to receive Janssen COVID-19 Vaccine.

†Immediate allergic reaction.
vaccine coadministration (e.g., tetanus-toxoid-containing vaccination as part of wound management, rabies vaccination for post-exposure prophylaxis, measles or hepatitis A vaccination during an outbreak) or to avoid barriers to or delays in COVID-19 vaccination.

†For the purpose of this guidance, an immediate allergic reaction is defined as any hypersensitivity-related signs or symptoms, such as urticaria, angioedema, respiratory distress (e.g., wheezing, stridor), or anaphylaxis that occur within 4 hours following exposure to a vaccine or medication.
Janssen COVID-19 Vaccine (Johnson & Johnson) Protocol Order for Administering Vaccine to Persons 18 Years of Age and Older

<table>
<thead>
<tr>
<th>Sex and Weight of Patient</th>
<th>Needle Gauge</th>
<th>Needle Length</th>
<th>Injection Site‡</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female or male fewer than 130 lbs</td>
<td>22–25</td>
<td>5/8&quot;–1&quot;</td>
<td>Deltoid muscle of arm</td>
</tr>
<tr>
<td>Female or male 130–152 lbs</td>
<td>22–25</td>
<td>1&quot;</td>
<td>Deltoid muscle of arm</td>
</tr>
<tr>
<td>Female 152–200 lbs</td>
<td>22–25</td>
<td>1–11/2&quot;</td>
<td>Deltoid muscle of arm</td>
</tr>
<tr>
<td>Male 152–260 lbs</td>
<td>22–25</td>
<td>1–11/2&quot;</td>
<td>Deltoid muscle of arm</td>
</tr>
<tr>
<td>Female 200+ lbs</td>
<td>22–25</td>
<td>11/2&quot;</td>
<td>Deltoid muscle of arm</td>
</tr>
<tr>
<td>Male 260+ lbs</td>
<td>22–25</td>
<td>11/2&quot;</td>
<td>Deltoid muscle of arm</td>
</tr>
</tbody>
</table>

‡Alternately, the anterolateral thigh can be used. A 1.5-inch needle may be used if administering vaccine in this site.

Follow the manufacturer’s guidance for storing/handling punctured vaccine vials.

Administer 0.5 mL Janssen COVID-19 Vaccine by intramuscular (IM) injection.

Document vaccination.

COVID-19 vaccination providers must document vaccine administration in their medical record systems and the Louisiana LINKS Immunization Registry within 24 hours of administration.

Document each recipient’s vaccine administration information:

- Medical record: The vaccine and the date it was administered, manufacturer, lot number, vaccination site and route, name and title of the person administering the vaccine
- Vaccination record card: Date of vaccination, product name/manufacturer, lot number, and name/location of the administering clinic or healthcare professional. Give to the vaccine recipient.
- Immunization information system (IIS): Report the vaccination to Louisiana LINKS as soon as possible, and no later than 24 hours after vaccination.

Additional preparation and administration information is available on the manufacturer’s website at www.janssencovid19vaccine.com.

Be prepared to manage medical emergencies.

Vaccination providers should observe patients after vaccination to monitor for the occurrence of immediate adverse reactions:

- **30 minutes:** Persons with a:
  - History of an immediate allergic reaction of any severity to a vaccine or injectable therapy
  - Contraindication to mRNA COVID-19 vaccines who receive Janssen vaccine
  - History of anaphylaxis due to any cause
- **15 minutes:** All other persons

Have a written protocol to manage medical emergencies following vaccination, as well as equipment and medications, including at least 3 doses of epinephrine, H1 antihistamine, blood pressure monitor, and timing device to assess pulse.

Healthcare personnel who are trained and qualified to recognize the signs and symptoms of anaphylaxis as well as administer intramuscular epinephrine should be available at the vaccination location at all times.

For more information, please see:

- CDC’s General Best Practice Guidelines for Immunization, “Preventing and Managing Adverse Reactions,” at https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/adverse-reactions.html
- Immunization Action Coalition’s “Medical Management of Vaccine Reactions in Adults in a Community Setting” at https://www.immunize.org/catg.d/p3082.pdf

Report adverse events to the Vaccine Adverse Event Reporting System (VAERS).

While this vaccine is under Emergency Use Authorization (EUA), healthcare professionals are required to report to VAERS:

- Vaccine administration errors (whether associated with an adverse event [AE] or not)
- Serious AEs (irrespective of attribution to vaccination)
- Multisystem inflammatory syndrome (MIS) in adults or children
- Cases of COVID-19 that result in hospitalization or death
- Any additional AEs and revised safety requirements per the Food and Drug Administration’s conditions for use of an authorized vaccine throughout the duration of the EUA

Healthcare professionals are encouraged to report to VAERS:

Clinically important adverse events that occur after vaccination, even if they are not sure whether the vaccine caused the adverse event
**Janssen COVID-19 Vaccine (Johnson & Johnson)**
Protocol for Administering Vaccine to Persons 18 Years of Age and Older

Adapted with appreciation from the Immunization Action Coalition (IAC) standing orders

**Table 1: Ingredients included in COVID-19 vaccines**
The following is a list of ingredients for the Pfizer-BioNTech, Moderna, and Janssen COVID-19 vaccines reported in the prescribing information for each vaccine.

<table>
<thead>
<tr>
<th>Description</th>
<th>Pfizer-BioNTech (mRNA)</th>
<th>Moderna (mRNA)</th>
<th>Janssen (viral vector)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Active ingredient</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nucleoside-modified mRNA encoding the viral spike (S) glycoprotein of SARS-CoV-2</td>
<td>Nucleoside-modified mRNA encoding the viral spike (S) glycoprotein of SARS-CoV-2</td>
<td>Recombinant, replication-incompetent Ad26 vector, encoding a stabilized variant of the SARS-CoV-2 Spike (S) protein</td>
<td></td>
</tr>
<tr>
<td><strong>Inactive ingredients</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide</td>
<td>PEG2000-DMG: 1, 2-dimyristoyl-rac-glycerol, methoxypolyethylene glycol</td>
<td>Polysorbate-80</td>
<td></td>
</tr>
<tr>
<td>1,2-distearoyl-sn-glycero-3-phosphocholine</td>
<td>1,2-distearoyl-sn-glycero-3-phosphocholine</td>
<td>2-hydroxypropyl-β-cyclodextrin</td>
<td></td>
</tr>
<tr>
<td>Cholesterol</td>
<td>Cholesterol</td>
<td>Citric acid monohydrate</td>
<td></td>
</tr>
<tr>
<td>(4-hydroxybutyl)azanediyl)bis(hexane-6,1-diy)bis(2-hexyldecanoate)</td>
<td>SM-102: heptadecane-9-yl 8-((2-hydroxyethyl) (6-oxo-6-(undecyloxy) hexyl) amino) octanoate</td>
<td>Trisodium citrate dihydrate</td>
<td></td>
</tr>
<tr>
<td>Potassium chloride</td>
<td>Tromethamine</td>
<td>Sodium chloride</td>
<td></td>
</tr>
<tr>
<td>Monobasic potassium phosphate</td>
<td>Tromethamine hydrochloride</td>
<td>Sodium hydroxide</td>
<td></td>
</tr>
<tr>
<td>Sodium chloride</td>
<td>Acetic acid</td>
<td>Hydrochloric acid</td>
<td></td>
</tr>
<tr>
<td>Dibasic sodium phosphate dihydrate</td>
<td>Sodium acetate</td>
<td>Ethanol</td>
<td></td>
</tr>
<tr>
<td>Sucrose</td>
<td>Sucrose</td>
<td>Water for injection</td>
<td></td>
</tr>
</tbody>
</table>

* None of the vaccines contain eggs, gelatin, latex, or preservatives.

Note: Both the Pfizer-BioNTech and Moderna COVID-19 vaccines contain polyethylene glycol (PEG). PEG is a primary ingredient in osmotic laxatives and oral bowel preparations for colonoscopy procedures, an inactive ingredient or excipient in many medications, and is used in a process called “pegylation” to improve the therapeutic activity of some medications (including certain chemotherapeutics). Additionally, cross-reactive hypersensitivity between PEG and polysorbates (included as an excipient in some vaccines and other therapeutic agents) can occur. Information on active or inactive ingredients in vaccines and medications can be found in the package insert. CDC’s vaccine excipient summary and the National Institutes of Health DailyMed database can also be used as resources.